Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Teclistamab: BCMA x CD3 bispecific antibody in RRMM

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, talks through the results from the Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).